Table 4 ASFV subunit vaccines tested in vivo that induced some level of protection
From: African swine fever vaccines: a promising work still in progress
Gene Name | Immunization | Challenge strain | Outcome | Haplotype | Reference |
|---|---|---|---|---|---|
A179L, B407L, B438L, B602L, B646L, Complement (183875–184,183), CP204L, CP2475L, CP530R, D117L, D339L, DP71L, E120R, E183L, E199L, EP153R, EP364R, EP402R, F1055L, F317L, G1211R, G1340L, H108R, I329L, K205R, KP177R, L10L, M1249L, MGF110-2 L, MGF110-4 L, MGF300-2R, MGF360-11 L, MGF360-15R, MGF360-18R, MGF360-1 L, MGF505-4R, MGF505-5R, NP1450L, NP419L & O61R | DNA prime + rVACV boost | Georgia 2007/1 | No surviving pigs Reduced viremia and viral loads in some tissues | Babraham | [73] |
B646L, CP204L, CP2475L (p37, p150), CP530R & E183L | rAd | Georgia 2007/1 | Partial protection: 5/9 surviving pigs versus 1/5 control pigs Reduced viremia depending on the adjuvant used Pigs recover from infection Authors claim that none of the immunogens conferred statistically significant protection | Outbred | |
A151R, B646L, C129R, CP204L, CP530R, E146L, I215L, I73R, L8L, M448R, MGF110-4 L & MGF110-5 L | rAd prime + MVA boost | OUR T88/1 | No surviving pigs 3/6 pigs with reduced and delayed clinical signs, 5/6 pigs with reduced viremia Reduced viral load in some tissues | Outbred | [38] |
CP2475L & A137R | Synthetic peptides | E70 | No surviving pigs Increased average survival Reduced mean viral titers | Outbred | [72] |
CP204L & B646L | Synthetic peptides | E70 | No surviving pigs Increased average survival Reduced mean viral titers | Outbred | [72] |
CP204L, E183L & EP402 | DNA (as a fusion with Ub) | E75 | Partial protection: 2/6 surviving pis Delayed clinical signs and viremia Pigs recover from the infection | Outbred | [89] |
CP312R | DNA expression library | E75 | Partial protection: 6/10 surviving pigs Reduced virus titers in blood, shedding and lesions Pigs recover from the infection | Outbred |